Geetha Shankar

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2021 · 483 citations · Full text

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2017 · 415 citations · Full text

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski et al. · Journal of Thoracic Oncology · 2021 · 283 citations · Full text

Neuro-oncology, Atezolizumab Plus Bevacizumab, Medicine +8

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Marcin Kowanetz, Wei Zou, Scott Gettinger et al. · Proceedings of the National Academy of Sciences · 2018 · 236 citations · Full text

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <i>KRAS-</i>mutated non-small cell lung cancer with <i>STK11</i>, <i>KEAP1,</i> or <i>TP53</i> comutations: subgroup results from the phase III IMpower150 trial

Howard West, Mark L. McCleland, Federico Cappuzzo et al. · Journal for ImmunoTherapy of Cancer · 2022 · 139 citations · Full text